People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Pharmaceuticals, Software / Tech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Saliogen Therapeutics, Inc. | — | Biotechnology | Series D+ | $152.2M | $3.4B | 2021 |
| Antios Therapeutics Inc. | — | Pharmaceuticals | Series C | $126.4M | $1.7B | 2021 |
| Gennao Bio, Inc. | — | Biotechnology | Series B | $47.5M | $211.8M | 2022 |
| Kollective Technology, Inc. | — | Software / Tech | Series A | $34.2M | $188.2M | 2016 |
| Amlogenyx Inc. | — | Biotechnology | Series A | $14.0M | $71.1M | 2024 |
| OTR Global Holdings II, Inc. | — | Other | Series A | $8.0M | $121.1M | 2009 |
Craig Gordon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Craig Gordon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd Johnson | 1 | 27 |
| Peter Thompson | 1 | 16 |
| Chau Khuong | 1 | 9 |
| Mark Koulogeorge | 1 | 8 |
| Stephen Squinto | 1 | 8 |
| Adam Koopersmith | 1 | 7 |
| Gregory Mayes | 1 | 5 |
| Sean Stalfort | 1 | 5 |
| Kirk Wolfe | 1 | 5 |
| Bradley Campbell | 1 | 5 |
| Stanton Green | 1 | 4 |
| Edgar Masri | 1 | 4 |
| NICOLE VITULLO | 1 | 4 |
| William O'Neill | 1 | 4 |
| Gary Sender | 1 | 3 |
| Iyona Rajkomar | 1 | 3 |
| Benjamin Rovinski | 1 | 3 |
| Tom Perry | 1 | 3 |
| Bruce Turner | 1 | 2 |
| Dan Vetras | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.